NEW YORK (GenomeWeb News) – Life Technologies has completed its previously announced series of senior notes offerings, bringing in net proceeds of around $1.48 billion, the firm said in a filing Friday with the US Securities and Exchange Commission.
The first tranche for $250 million in 3.375 percent notes matures March 1, 2013; the second tranche of $500 million in 4.4 percent notes matures March 1, 2015; and the third tranche of $750 million in 6 percent notes matures March 1, 2020.
Life Technologies said that it would use the proceeds from the offering to repay all of the outstanding indebtedness under its term loan A facility and term loan B facility of its credit agreement. As of Dec. 31, 2009, the firm had $1.33 billion outstanding under the term loan A facility, with a maturity date of Nov. 21, 2013, and $643 million outstanding under the term loan B facility, with a maturity date of Nov. 21, 2015.
That credit facility was used in part to finance the November 2008 acquisition of Applied Biosystems by Invitrogen, the predecessor companies of Life Technologies.
Following the senior notes offering, Life Technologies said that its fiscal-year 2010 interest expense is now expected to be between $110 million and $120 million, including amortization of debt issuance costs. Its non-GAAP earnings per share guidance is still expected to be between $3.30 and $3.50.